Abstract:Extracellular vesicles (EVs) have gained widespread interest due to their potential in the diagnosis and treatment of inflammation, autoimmune diseases, and cancers. EVs are lipidic vesicles comprising vesicles of endosomal origin called exosomes, microvesicles from membrane shedding, and apoptotic bodies from programmed cell death membrane blebbing that carry complex sets of cargo from their cells of origin, including proteins, lipids, mRNA, and DNA. EVs are rich in integrin proteins that facilitate intrinsic cellular communication to deliver their cargo contents and can also be used as biomarkers to study respective cellular conditions. Within this background, we hypothesized that when these EVs are hybridized with synthetic liposomes, it would help navigate the hybrid construct in the complex biological environment to find its target. Toward this endeavor, we have hybridized a synthetic liposome with EVs (herein called LEVs) derived from mouse breast cancer (4T1 tumors) cells and incorporated a rhodamine-B/near-infrared fluorescent dye to investigate their potential for cellular targeting and tumor delivery. Using membrane extrusion, we have successfully hybridized both entities resulting in the formation of LEVs and characterized their colloidal properties and stability over a period. While EVs are broadly dispersed nano- and micron-sized vesicles, LEVs are engineered as monodispersed with an average hydrodynamic size of 140 ± 5. Using immunoblotting and ELISA, we monitored and quantified the EV-specific protein CD63 and other characteristic proteins such as CD9 and CD81, which were taken as a handle to ensure the reproducibility of EVs and thus LEVs. These LEVs were further challenged with mice bearing orthotopic 4T1 breast tumors and the LEV uptake was found to be maximum in tumors and organs like the liver, spleen, and lungs when compared to control PEGylated liposomes in live animal imaging. Likewise, the constructs were capable of finding lung metastasis as observed in ex vivo imaging. We anticipate that this study can open avenues for drug delivery solutions that are superior in target recognition.

Homologous tumor cell membrane vesicles active preferential self-recognition of tumor cells in vitro

Cellular-Membrane-Derived Vesicles for Cancer Immunotherapy

Phospholipid-Membrane-Based Nanovesicles Acting as Vaccines for Tumor Immunotherapy: Classification, Mechanisms and Applications

Hybrid Vesicles Based on Autologous Tumor Cell Membrane and Bacterial Outer Membrane To Enhance Innate Immune Response and Personalized Tumor Immunotherapy

Tumor Cell Membrane Biomimetic Liposomes-Coated Oncolytic Viruses to Target the Homotypic Tumor and Augment the Antitumor Efficacy

Tumor-derived microvesicles for cancer therapy

Bacterial Vesicle-Cancer Cell Hybrid Membrane-Coated Nanoparticles for Tumor Specific Immune Activation and Photothermal Therapy

Supramolecular engineering of cell membrane vesicles for cancer immunotherapy

Cell Membrane-Derived Vesicle: A Novel Vehicle for Cancer Immunotherapy

Cell-derived biomimetic nanocarriers for targeted cancer therapy: cell membranes and extracellular vesicles

A Self-Delivery Membrane System for Enhanced Anti-Tumor Therapy

Dual-targeting nanovesicles enhance specificity to dynamic tumor cells <i>in vitro</i> and <i>in vivo via</i> manipulation of v3-ligand binding

Maximizing liposome tumor delivery by hybridizing with tumor-derived extracellular vesicles

The Application of Bacterial Outer Membrane Vesicles in Tumor Treatment

Biomembrane-based nanostructures for cancer targeting and therapy: From synthetic liposomes to natural biomembranes and membrane-vesicles

Cell Membrane-Coated Nanoparticles for Tumor-Targeted Drug Delivery

Dual-targeting nanovesicles enhance specificity to dynamic tumor cells in vitro and in vivo via manipulation of αvβ3-ligand binding

Extracellular Vesicles: A New Perspective in Tumor Therapy

in vitro Model for Targeting Tumor Vasculature Using Immunoliposome

Application of engineered extracellular vesicles for targeted tumor therapy

Tumor cell-derived exosomes home to their cells of origin and can be used as Trojan horses to deliver cancer drugs